Additional Information
Market: NYSE
Sector: Medical
EPIC: DGX
Latest Price: 61.47  (0.18% Ascending)
52-week High: 64.08
52-week Low: 50.80
Market Cap: 8,877.17M
1 year chart
1 day chart
Quest Diagnostics
www.questdiagnostics.com

Quest Diagnostics Incorporated is a provider of diagnostic testing, information and services. The Company offers United States patients and physicians access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides clinical testing, including gene-based and other esoteric testing, anatomic pathology services, including dermatopathology and testing for drugs-of-abuse, and risk assessment services for the life insurance industry. It also provides testing for clinical trials. Its diagnostics products business manufactures and markets the United States Food and Drug Administration (FDA) cleared or approved diagnostic test kits and specialized point-of-care testing.

Quest Diagnostics’ Subsidiary Receives FDA Approval For Simplexa Flu Test

1st Dec 2010, 7:28 pm
Quest Diagnostics’ Subsidiary Receives FDA Approval For Simplexa Flu Test

Quest Diagnostics (NYSE: DGX), a provider of diagnostic testing services based in Madison, New Jersey, announced today that the U.S. Food and Drug Administration (FDA) has approved its Focus Diagnostics subsidiary’s Simplexa flu test. 


The Simplexa test is intended to help detect influenza A, influenza B and RSV infections, which can sometimes cause severe illnesses, especially in children.  These viruses can be hard to diagnose since their signs and symptoms are similar to other respiratory viruses. 


According to the U.S. Centers for Disease Control and Prevention, twenty five to 40 percent of infants and young children with RSV infection show signs of pneumonia or bronchiolitis, and it is estimated that between 75,000 and 125,000 children less than one year old are hospitalized each year due to RSV.


According to Quest, it is expected that results from the Simplexa test can be reported in less than three hours after receiving a virus specimen.   


"For many physicians and lab administrators, it will eliminate the time-consuming step of sending a specimen to a reference lab for molecular testing to detect flu and RSV infection,” said John G. Hurrell, Vice President of Focus Diagnostics.


Also, results of a clinical study that was part of the FDA approval process found the Simplexa test performed comparably to other devices in detecting the target viruses.  


Since the announcement, the Quest’s share price has rallied 1.6% to trade at $50.12 as of 2:17 pm EST.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here